J&J’s Strong Phase 1 Prostate Cancer Data Intensifies Competitive Pressure on Oric
Oric shares declined after Johnson & Johnson reported a 75% tumor response rate with JNJ-6143 in heavily pretreated advanced prostate cancer patients.
Oric shares declined after Johnson & Johnson reported a 75% tumor response rate with JNJ-6143 in heavily pretreated advanced prostate cancer patients.
J&J reports Q3 revenue of $25.4B and adjusted EPS of $2.59, beating estimates. Tremfya sales surge 68% while Middle East conflict weighs on medical device results.
Contineum said its J&J-partnered drug PIPE-307 missed the Phase 2 primary goal of improving MADRS scores at Day 5 versus placebo.
J&J is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to Apollo for about $20B. A deal could close in weeks—or J&J may spin it off.
60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.
Johnson & Johnson cuts 2026 adjusted EPS guidance to $10.96–$11.11 after its $1B Firefly Bio acquisition and Sail Biomedicines partnership.